Heart failure: three biomarkers that can predict patient outcome

Heart failure represents the final stage for many cardiovascular diseases and is one of the main causes of hospitalization and death in the Western world. A recent study has identified a method that analyzes the presence of three biomarkers in the blood, allowing us to predict the outcome of patients with heart failure and evaluate the probability of hospitalization. 

Predicting the patient outcome through science

Italy is at the forefront with this study, published in the prestigious Journal of the American College of Cardiology and conducted by Italian researchers from the Scuola Superiore Sant’Anna in Pisa and the Gabriele Monasterio Foundation (Michele Emdin, Alberto Aimo, Claudio Passino, Giuseppe Vergaro, Andrea Ripoli) alongside scholars from important European and American research centers. Researchers have demonstrated that the quantity of three biomarkers in the blood can give important information about the clinical outcomes of patients with heart disease. 

The three biomarkers that make up this research are: 

  • Soluble Sst2 receptor, an important indicator of the activation of pathways that cause the heart to weaken through fibrosis
  • Cardiac hormone Nt-probnp, for the hemodynamic measurement of decompensated heart failure 
  • High-sensitive cardiac troponin T, indicator of cell death. 

In order to predict “reliable” outcomes, the data from each of the three biomarkers must be cross-correlated. Data was gathered from 4,268 patients with decompensated heart failure and analyzed through advanced statistical methods. Findings demonstrated that the analysis of all three biomarkers allows for risk stratification at an individual level, classifying patients into low, medium or high risk groups and, consequently, helps determine the type of therapy to be administered and how often follow-up visits should be scheduled.  

scompenso-cardiaco-tre-biomarcatori-prevedono-il-futuro-clinico-dei-malati

Moving towards more specific therapies

One of the important new points of the study is the dose of sSt2. Routinely used to diagnose acute myocardial infarction, sSt2 is now also used as a new instrument in decompensated heart failure along with the hormone Nt-probnp and troponin. “It’s definitely an original observation”, states cardiologists Michele Emdin and Claudio Passino, “which has aroused great interest in the world of cardiology across the globe. The results published confirm the importance of combining these three biomarkers for the integrated assessment of patients with cardiac diseases, as well as the development of new diagnostic instruments and new treatments for more frequent and dangerous diseases”. Without a doubt these findings give new hope to patients with heart disease and represent an important breakthrough in  precision medicine, providing a new diagnostic instrument to rely on for more personalized treatment.

© Domedica s.r.l.

Share this article

Share on facebook
Share on twitter
Share on linkedin
Share on email

Related Articles

Our Services

Over 10 years of experience in designing and executing Patient Support Programmes and Support Programmes for Physicians, Clinical Centres and other Constituencies in Health Care.

Our Programmes enhance the quality and effectiveness of care, improve therapy adoption and increase long-term adherence.

We conduct Home Clinical Trials, Observational and Clinical Studies, Behavioural Research, Insights and Impact Analyses, both at an Italian and International level.

Our Projects document, leverage and disseminate high-impact evidence on Therapies and Therapeutic Approaches.

We design and execute multi-channel, e-detailing and online marketing and promotion projects.

We help Clients build and develop long-lasting relationships with key Constituencies, supporting their commercial and promotional strategies.